ASX-LISTED Eagle Health Holdings has reported first quarter sales remain "on budget" driven by strong ongoing growth in protein powders and amino acid ranges.
Sales for the three months to 31 Mar were $19.8 million, with the company saying its newly launched Hutang-1 diabetes product had now reached over 80,000 consumers in its key target market of China, including 24,000 diabetic or pre-diabetic patients, and showed "promising conversion to sales".
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 18
